Select Topic:
Browse by Series:

Advanced Prostate Cancer: Closing Thoughts

Panelists: Joe OSullivan, MD, FRCPI, FFRRCSI, FRCR, The Northern Ireland Cancer Centre, Belfast City Hospital; Johann de Bono, PhD, MB, ChB, Institute of Cancer Research, Royal Marsden Hospital; Chris Parker, MD, FRCR, MRCP, Institute of Cancer Research, Royal Marsden Hospital; Bertrand Tombal, MD, PhD, Cliniques Universitaires Saint-Luc
Published Online: Monday, Nov 13, 2017



Transcript: 

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Gentlemen, we’ve had a great discussion. We’ve covered a lot of information regarding personalized therapy in metastatic prostate cancer. Before we end, I’d like to invite each of you to share any additional comments you might have based on what we’ve discussed. Bertrand, can I start with you? Do you have any additional comment to make?

Bertrand Tombal, MD, PhD: We live in an exciting phase. But, once again, it’s a phase where we can do a lot of good, but we can do a lot of harm. So, we have to think on what we do and not jump on the first hype, still try to better deliver what we know is working well, and then go to the hype.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Johann?

Johann de Bono, PhD, MB, ChB: I think my main piece of advice is 2-fold. One is to get the drugs into the patients before they get sick. Don’t give abiraterone after enzalutamide or enzalutamide after abiraterone and then wait so long that they’re never going to get drugs, like radium or the taxanes. Please make sure you get all the drugs in before the patients die. And secondly, don’t just monitor PSA as your response measure. Do scans and ensure that you know whether the patient is radiologically responding or not.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Chris, any last words of wisdom?

Chris Parker, MD, FRCR, MRCP: Johann stole my point. I was going to say that the most important takeaway message is that we’ve got to find drugs that improve survival and you want as many of your patients as possible to benefit from as many of those 5 drugs as possible. You don’t want them to die after having 1 or 2.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Great. Thank you. It’s been a great discussion. Thank you all for your contributions to this program, and, on behalf of our panel here, we’d like to thank you, our viewers, for joining us. Thanks very much.

Transcript Edited for Clarity 
 

Slider Left
Slider Right


Transcript: 

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Gentlemen, we’ve had a great discussion. We’ve covered a lot of information regarding personalized therapy in metastatic prostate cancer. Before we end, I’d like to invite each of you to share any additional comments you might have based on what we’ve discussed. Bertrand, can I start with you? Do you have any additional comment to make?

Bertrand Tombal, MD, PhD: We live in an exciting phase. But, once again, it’s a phase where we can do a lot of good, but we can do a lot of harm. So, we have to think on what we do and not jump on the first hype, still try to better deliver what we know is working well, and then go to the hype.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Johann?

Johann de Bono, PhD, MB, ChB: I think my main piece of advice is 2-fold. One is to get the drugs into the patients before they get sick. Don’t give abiraterone after enzalutamide or enzalutamide after abiraterone and then wait so long that they’re never going to get drugs, like radium or the taxanes. Please make sure you get all the drugs in before the patients die. And secondly, don’t just monitor PSA as your response measure. Do scans and ensure that you know whether the patient is radiologically responding or not.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Chris, any last words of wisdom?

Chris Parker, MD, FRCR, MRCP: Johann stole my point. I was going to say that the most important takeaway message is that we’ve got to find drugs that improve survival and you want as many of your patients as possible to benefit from as many of those 5 drugs as possible. You don’t want them to die after having 1 or 2.

Joe O’Sullivan, MD, FRCPI, FFRRCSI, FRCR: Great. Thank you. It’s been a great discussion. Thank you all for your contributions to this program, and, on behalf of our panel here, we’d like to thank you, our viewers, for joining us. Thanks very much.

Transcript Edited for Clarity 
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x